On the morning of April 25, a delegation led by Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League and Chairman of the All-China Youth Federation, visited CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK), for inspection and guidance.

Chemotherapy is one of the core methods of tumor treatment, but chemotherapy-induced neutropenia (CIN) is the most common hematological adverse event in clinical practice. The resulting febrile neutropenia (FN) can lead to chemotherapy dose reduction, delays, and even endanger patient safety. On April 23, the "Chinese Expert Consensus on the Diagnosis and Treatment of Chemotherapy-Induced Neutropenia (2026)" was officially released.

From April 17 to 22, local time, the 2026 American Association for Cancer Research (AACR) Annual Meeting was held in San Diego. As one of the most influential academic events in the global oncology research field, LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical (1177.HK), disclosed for the first time key preclinical research data for two globally competitive next-generation antibody-drug conjugates (ADCs) - LM-364TME and LM-338.

From April 17 to 22, local time, the 2026 American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA. LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical (1177.HK), announced for the first time preliminary clinical data for its independently developed innovative drug MK-2010/LM-299 (a PD-1/VEGF bispecific antibody).

On April 17, the official website of the National Medical Products Administration (NMPA) showed that the 4th indication for the Class 1 new drug "Defu Combination" from CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK)—Benmelstobart (Andewei®) combined with Anlotinib capsules (Fukewei®)—has been approved for marketing for the treatment of advanced or unresectable alveolar soft tissue sarcoma (ASPS).

On April 15, LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical (1177.HK), announced the successful enrollment of the first patient in the Phase III registrational clinical trial of its independently developed Class 1 new drug, Tecotabart vedotin (LM-302, a CLDN18.2 ADC), combined with a PD-1 inhibitor for the first-line treatment of CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

On April 13, the "China-UAE Business and Investment Promotion Conference", jointly hosted by the Ministry of Commerce of the People's Republic of China and the Ministry of Foreign Trade of the United Arab Emirates, was held in Beijing.

From "emerging and cultivating" to a "strategic pillar", as China's biopharmaceutical industry enters a new stage of high-quality development, mere capacity expansion is no longer the sole measure of a company's core competitiveness.

On April 8 (local time), Kylo-11 (LPA-siRNA), independently developed by Hygieia, a wholly-owned subsidiary of Sino Biopharmaceutical (1177.HK), achieved the enrollment of the first US patient in the United States for its Phase II clinical trial in patients with atherosclerotic cardiovascular diease (ASCVD) and elevated lipoprotein (a) [Lp(a)].

Opioid-induced constipation (OIC) is one of the most common symptoms in cancer patients, affecting approximately 60%-90% of cancer patients using opioids for pain relief.